Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Lytix Biopharma AS (LYTIX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.60 +0.02    +0.36%
13:47:34 - Closed. Currency in NOK ( Disclaimer )
  • Volume: 6,750
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 5.42 - 5.62
Type:  Equity
Market:  Norway
ISIN:  NO0010405780 
S/N:  NO0010405780
Lytix Biopharma AS 5.60 +0.02 +0.36%

Lytix Biopharma AS Company Profile

 
Read the Lytix Biopharma AS company profile to learn more about the business and the management team. View Lytix Biopharma AS facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

8

Equity Type

ORD

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.

Contact Information

Address Sandakerveien 138
Oslo, 0484
Norway
Phone -
Fax -

Top Executives

Name Age Since Title
Sudhir Agrawal 69 - Member of Scientific Advisory Board
Robert H.I. Andtbacka - - Member of Scientific Advisory Board
James Patrick Allison - 2019 Member of Scientific Advisory Board
Aurelien Marabelle - - Member of Scientific Advisory Board
Kjetil Hestdal 63 2021 Non-Executive Independent Director
Jayson M. Rieger 47 2021 Non-Executive Independent Director
Brynjar Kristian Forbergskog 65 2021 Non-Executive Independent Director
Sandra Demaria - - Member of Scientific Advisory Board
Marie Ann Roskrow - 2023 Chairperson
Padmanee Sharma - 2019 Member of Scientific Advisory Board
Evelina Vagesjo - 2021 Non-Executive Independent Director
Marie-Louise Helena Fjallskog 60 2021 Interim CMO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LYTIX Price Commentary

Write your thoughts about Lytix Biopharma AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email